Osuga Yutaka, Torng Pao-Ling, Jeng Cherng-Jye
a Department of Obstetrics and Gynecology , University of Tokyo , Tokyo , Japan.
b Department of Obstetrics and Gynecology , National Taiwan University Hospital , Hsin-Chu , Taiwan.
J Obstet Gynaecol. 2019 Apr;39(3):291-296. doi: 10.1080/01443615.2018.1460584. Epub 2019 Jan 17.
We aimed to examine how leuprorelin has been studied for the treatment of women with endometriosis in Asia. We conducted a literature search of PubMed, the Cochrane Library and ClinicalTrials.gov. This review includes randomised trials of women with endometriosis treated with leuprorelin in Asia. Phase I-IV clinical trials published between January 1 2000 and December 31 2016 and written in English were included. Four studies were identified, showing that leuprorelin significantly improves pain and quality of life. The oestrone and oestradiol levels are decreased by leuprorelin but can be increased using an 'add-back' therapy with conjugated equine oestrogen and methoxyprogesterone. Menopause is more common in women treated with leuprorelin. The bone mineral density is reduced in women treated with leuprorelin. There are limited studies investigating the use of leuprorelin for the treatment of endometriosis in Asian populations. However, the research that has been conducted supports the use of leuprorelin in an Asian population.
我们旨在研究在亚洲亮丙瑞林用于治疗子宫内膜异位症女性的相关研究情况。我们对PubMed、考克兰图书馆和ClinicalTrials.gov进行了文献检索。本综述纳入了在亚洲进行的亮丙瑞林治疗子宫内膜异位症女性的随机试验。纳入了2000年1月1日至2016年12月31日期间发表且为英文撰写的I-IV期临床试验。共识别出四项研究，结果显示亮丙瑞林能显著改善疼痛和生活质量。亮丙瑞林可降低雌酮和雌二醇水平，但使用结合马雌激素和甲羟孕酮进行“反向添加”治疗可使其升高。接受亮丙瑞林治疗的女性更易出现绝经。接受亮丙瑞林治疗的女性骨矿物质密度降低。关于亮丙瑞林在亚洲人群中治疗子宫内膜异位症的研究有限。然而，已开展的研究支持在亚洲人群中使用亮丙瑞林。
